Treatment with AT-001, a highly selective aldose reductase inhibitor, had no significant effect on exercise capacity as measured by peak oxygen uptake (VO2) among individuals with diabetic cardiomyopathy, according to results from this Late-Breaking Clinical Trial presented at ACC.24 and simultaneously published in JACC.

Ninerafaxstat, a novel cardiac mitotrope that targets energy metabolism, is safe and effective in the treatment of nonobstructive hypertrophic cardiomyopathy (HCM), according to the phase 2 IMPROVE-HCM study, presented during a Late-Breaking Clinical Trial session at ACC.24 and simultaneously published in JACC.

In patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C levels <70 mg/dL, immediately adding inclisiran led to greater reductions in LDL-C, according to results of the open-label, phase 3b VICTORION-INITIATE study presented during a Featured Clinical Research session at ACC.24 and simultaneously published in JACC.

The majority (>90%) of participants using a novel web application appropriately qualified for treatment with a nonprescription statin, closely matching results of a clinician assessment of eligibility, according to results from TACTiC, presented during a Late-Breaking Clinical Trial session at ACC.24 and simultaneously published in JACC.

A robust telemedicine intervention across six months following an acute coronary syndrome (ACS) was associated with a reduction in hospital readmission, emergency department (ED) visits, unplanned coronary revascularization and patient-reported symptoms, according to a study presented during a Featured Clinical Research session at ACC.24 and simultaneously published in JACC.